Element Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Element Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-52,528	Closed	-$205K	–	1115
2018 Q1	$205K	Buy	+52,528	New	+$185K	﹤0.01%	673

Other funds holding CTIC

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Element Capital Management's CTIC Position: Q2 2018 in Review

Element Capital Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2018, closing a stake of 52,528 shares — an estimated $205K sold.

Element Capital Management first reported a position in CTIC in Q1 2018 and held it in 1 quarter. The position peaked at $205K in Q1 2018. 83 funds tracked by Wall St. Rank hold CTIC as of Q2 2018.

Element Capital Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2018 after selling out during the quarter.
Element Capital Management sold 52,528 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2018, an estimated $205K.
Element Capital Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2018 and held it in 1 quarter.
Element Capital Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $205K in Q1 2018.
83 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2018.

Based on Element Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.